治疗去势抵抗性前列腺癌的新策略
Novel Strategies for Treating Castration-Resistant Prostate Cancer.
作者信息
Leung David Ka-Wai, Chiu Peter Ka-Fung, Ng Chi-Fai, Teoh Jeremy Yuen-Chun
机构信息
S. H. Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China.
出版信息
Biomedicines. 2021 Mar 27;9(4):339. doi: 10.3390/biomedicines9040339.
Abstract
The development of castration resistance is an inevitable pathway for the vast majority of patients with advanced prostate cancer. Recently, there have been significant breakthroughs in the understanding and management options of castration-resistant prostate cancer. Three novel hormonal agents showed survival benefits in non-metastatic patients. As for metastatic disease, there was an even wider range of management options being investigated. This review summarized advances in the management of castration-resistant prostate cancer (CRPC) including emerging data on novel imaging techniques and treatment strategies.
摘要
对于绝大多数晚期前列腺癌患者而言，去势抵抗的发展是一条不可避免的路径。近来，在去势抵抗性前列腺癌的认识和治疗选择方面取得了重大突破。三种新型激素药物在非转移性患者中显示出生存获益。至于转移性疾病，正在研究更广泛的治疗选择。本综述总结了去势抵抗性前列腺癌（CRPC）治疗方面的进展，包括新型成像技术和治疗策略的新数据。
相似文献
1
Novel Strategies for Treating Castration-Resistant Prostate Cancer.治疗去势抵抗性前列腺癌的新策略
Biomedicines. 2021 Mar 27;9(4):339. doi: 10.3390/biomedicines9040339.
2
Current management of advanced and castration resistant prostate cancer.晚期及去势抵抗性前列腺癌的当前管理
Can J Urol. 2014 Apr;21(2 Supp 1):1-6.
3
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.局部晚期和转移性前列腺癌的系统治疗进展：精准肿瘤学时代下转移性去势抵抗性前列腺癌的管理。
Eur Urol. 2019 Jan;75(1):88-99. doi: 10.1016/j.eururo.2018.03.028. Epub 2018 Apr 16.
4
Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy.针对未经激素治疗及去势抵抗性前列腺癌（无论是否接受过化疗）的激素疗法进展。
Exp Hematol Oncol. 2016 Jun 22;5:15. doi: 10.1186/s40164-016-0046-1. eCollection 2015.
5
Metastatic castration resistant prostate cancer: current strategies of management in the Middle East.转移性去势抵抗性前列腺癌：中东地区当前的管理策略
Crit Rev Oncol Hematol. 2014 Apr;90(1):36-48. doi: 10.1016/j.critrevonc.2013.11.001. Epub 2013 Nov 8.
6
Role of the Androgen-Androgen Receptor Axis in the Treatment Resistance of Advanced Prostate Cancer: From Androgen-Dependent to Castration Resistant and Further.雄激素-雄激素受体轴在晚期前列腺癌治疗抵抗中的作用：从雄激素依赖到去势抵抗及更远期情况
J UOEH. 2016 Jun 1;38(2):129-38. doi: 10.7888/juoeh.38.129.
7
Mechanisms of resistance in castration-resistant prostate cancer (CRPC).去势抵抗性前列腺癌（CRPC）的耐药机制。
Transl Androl Urol. 2015 Jun;4(3):365-80. doi: 10.3978/j.issn.2223-4683.2015.05.02.
8
Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.前列腺特异性抗原对延迟联合雄激素阻断治疗的反应预测了去势抵抗性前列腺癌患者后续雌激素和多西他赛治疗后的生存。
BJU Int. 2012 Oct;110(8):1149-55. doi: 10.1111/j.1464-410X.2012.10959.x. Epub 2012 Feb 28.
9
The changing landscape of advanced and castration resistant prostate cancer: latest science and revised definitions.晚期和去势抵抗性前列腺癌的不断变化态势：最新科学进展与修订定义
Can J Urol. 2014 Apr;21(2 Supp 1):7-13.
10
Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment.应对非转移性去势抵抗性前列腺癌：治疗中的特殊考量
Expert Rev Anticancer Ther. 2017 Jul;17(7):625-633. doi: 10.1080/14737140.2017.1333903. Epub 2017 May 31.
引用本文的文献
1
Nanotechnology in prostate cancer: a bibliometric analysis from 2004 to 2023.前列腺癌中的纳米技术：2004年至2023年的文献计量分析
Discov Oncol. 2025 Apr 2;16(1):451. doi: 10.1007/s12672-025-02265-0.
2
Synergistic Anti-tumorigenic Effects of Cabazitaxel and Usnic Acid Combination on Metastatic Castration-Resistant Prostate Cancer Cells.卡巴他赛与松萝酸联合应用对转移性去势抵抗性前列腺癌细胞的协同抗肿瘤作用
Anticancer Agents Med Chem. 2025;25(9):610-619. doi: 10.2174/0118715206336754241015062614.
3
Heme Oxygenase-1 and Prostate Cancer: Function, Regulation, and Implication in Cancer Therapy.血红素加氧酶-1 与前列腺癌：功能、调控及其在癌症治疗中的意义。
Int J Mol Sci. 2024 Aug 24;25(17):9195. doi: 10.3390/ijms25179195.
4
Heat shock proteins as hallmarks of cancer: insights from molecular mechanisms to therapeutic strategies.热休克蛋白作为癌症的标志：从分子机制到治疗策略的见解。
J Hematol Oncol. 2024 Sep 4;17(1):81. doi: 10.1186/s13045-024-01601-1.
5
Dysregulated microRNAs in prostate cancer: prediction and validation.前列腺癌中失调的微小RNA：预测与验证
Iran J Basic Med Sci. 2024;27(5):611-620. doi: 10.22038/IJBMS.2024.75164.16299.
6
TAS3681, an androgen receptor antagonist, prevents drug resistance driven by aberrant androgen receptor signaling in prostate cancer.TAS3681是一种雄激素受体拮抗剂，可预防前列腺癌中异常雄激素受体信号传导驱动的耐药性。
Mol Oncol. 2024 Aug;18(8):1980-2000. doi: 10.1002/1878-0261.13641. Epub 2024 Apr 10.
7
Precision Medicine in Castration-Resistant Prostate Cancer: Advances, Challenges, and the Landscape of PARPi Therapy-A Narrative Review.精准医学在去势抵抗性前列腺癌中的应用：PARPi 治疗的进展、挑战和前景——一篇叙述性综述。
Int J Mol Sci. 2024 Feb 11;25(4):2184. doi: 10.3390/ijms25042184.
8
Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial.尼拉帕利联合醋酸阿比特龙和泼尼松治疗转移性去势抵抗性前列腺癌和同源重组修复基因改变患者：随机 III 期 MAGNITUDE 试验的第二次中期分析。
Ann Oncol. 2023 Sep;34(9):772-782. doi: 10.1016/j.annonc.2023.06.009. Epub 2023 Jul 1.
9
Molecular Targeted Therapies in Metastatic Prostate Cancer: Recent Advances and Future Challenges.转移性前列腺癌的分子靶向治疗：最新进展与未来挑战
Cancers (Basel). 2023 May 23;15(11):2885. doi: 10.3390/cancers15112885.
10
Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16).多西他赛治疗后疾病无进展的转移性去势抵抗性前列腺癌患者用达罗他胺维持治疗（SAKK 08/16）。
J Clin Oncol. 2023 Jul 10;41(20):3608-3615. doi: 10.1200/JCO.22.01726. Epub 2023 Feb 8.
本文引用的文献
1
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer.EAU-EANM-ESTRO-ESUR-SIOG 前列腺癌诊治指南。第二部分-2020 年更新：复发性和转移性前列腺癌的治疗。
Eur Urol. 2021 Feb;79(2):263-282. doi: 10.1016/j.eururo.2020.09.046. Epub 2020 Oct 7.
2
Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib.聚腺苷二磷酸核糖聚合酶抑制剂在转移性去势抵抗性前列腺癌中的疗效与非 BRCA DNA 修复改变有很大不同：奥拉帕利治疗转移性去势抵抗性前列腺癌的 III 期 PROfound 试验中 B 队列预先指定终点的重建。
Eur Urol. 2021 Apr;79(4):442-445. doi: 10.1016/j.eururo.2020.09.024. Epub 2020 Oct 1.
3
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a or Gene Alteration.芦卡帕利治疗携带 或 基因改变的转移性去势抵抗性前列腺癌男性患者的疗效。
J Clin Oncol. 2020 Nov 10;38(32):3763-3772. doi: 10.1200/JCO.20.01035. Epub 2020 Aug 14.
4
Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.前列腺癌种系检测的实施：费城前列腺癌共识会议 2019 年。
J Clin Oncol. 2020 Aug 20;38(24):2798-2811. doi: 10.1200/JCO.20.00046. Epub 2020 Jun 9.
5
Olaparib for Metastatic Castration-Resistant Prostate Cancer.奥拉帕利治疗转移性去势抵抗性前列腺癌。
N Engl J Med. 2020 May 28;382(22):2091-2102. doi: 10.1056/NEJMoa1911440. Epub 2020 Apr 28.
6
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.奥拉帕利治疗伴有 DNA 修复基因异常的转移性去势抵抗性前列腺癌患者（TOPARP-B）：一项多中心、开放标签、随机、2 期临床试验。
Lancet Oncol. 2020 Jan;21(1):162-174. doi: 10.1016/S1470-2045(19)30684-9. Epub 2019 Dec 2.
7
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study.帕博利珠单抗治疗难治性转移性去势抵抗性前列腺癌：多队列、开放标签的 KEYNOTE-199 研究。
J Clin Oncol. 2020 Feb 10;38(5):395-405. doi: 10.1200/JCO.19.01638. Epub 2019 Nov 27.
8
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.卡巴他赛对比阿比特龙或恩杂鲁胺用于转移性前列腺癌。
N Engl J Med. 2019 Dec 26;381(26):2506-2518. doi: 10.1056/NEJMoa1911206. Epub 2019 Sep 30.
9
Progression-directed Therapy for Oligoprogression in Castration-refractory Prostate Cancer.寡转移去势抵抗性前列腺癌的进展导向治疗
Eur Urol Oncol. 2021 Apr;4(2):305-309. doi: 10.1016/j.euo.2019.08.012. Epub 2019 Sep 23.
10
TCF4 induces enzalutamide resistance via neuroendocrine differentiation in prostate cancer.TCF4 通过前列腺癌细胞的神经内分泌分化诱导恩扎卢胺耐药。
PLoS One. 2019 Sep 19;14(9):e0213488. doi: 10.1371/journal.pone.0213488. eCollection 2019.
Zotero 插件